Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings


Prévention et traitement du VIH/SIDA dans les pays à ressources limitées


Prevención y tratamiento del VIH/SIDA en entornos con recursos limitados



Daniel R. Hogan; Joshua A. Salomon1

Harvard Center for Population and Development Studies, Harvard School of Public Health, 9 Bow Street, Cambridge, MA 02138, USA




Strategies for confronting the epidemic of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) have included a range of different approaches that focus on prevention and treatment. However, debate persists over what levels of emphasis are appropriate for the different components of the global response. This paper presents an overview of this debate and briefly summarizes the evidence on a range of interventions designed to prevent the spread of HIV infection, paying particular attention to voluntary counselling and testing, treatment for sexually transmitted infections and prevention of mother-to-child transmission. We also review the experience with antiretroviral therapy to date in terms of response rates and survival rates, adherence, drug resistance, behavioural change and epidemiological impact. Although various studies have identified strategies with proven effectiveness in reducing the risks of HIV infection and AIDS mortality, considerable uncertainties remain. Successful integration of treatment and prevention of HIV/AIDS will require a balanced approach and rigorous monitoring of the impact of programmes in terms of both individual and population outcomes.

Keywords: HIV infections/prevention and control/drug therapy; Acquired immunodeficiency syndrome/prevention and control/drug therapy; Anti-retroviral agents/therapeutic use; Antiretroviral therapy, Highly active/utilization; Counseling; Disease transmission, Vertical/prevention and control; Sexually transmitted diseases/prevention and control; Treatment outcome; Evidence-based medicine; Developing countries (source: MeSH, NLM).


Parmi les stratégies qui ont été opposées à l'épidémie de VIH/SIDA, on peut mentionner diverses approches axées sur la prévention et le traitement. Cependant, les débats se poursuivent sur l'importance à accorder aux différentes composantes de la réponse mondiale. Le présent article présente une synthèse de ces débats et résume brièvement les données relatives à une série d'interventions destinées à prévenir la propagation de l'infection à VIH, en accordant une attention particulière au conseil et au dépistage volontaires, au traitement des infections sexuellement transmissibles et à la prévention de la transmission mère-enfant. Les auteurs examinent également l'expérience acquise à ce jour avec les traitements antirétroviraux en termes de taux de réponse et de survie, d'observance du traitement, de résistance médicamenteuse, de changement des comportements et d'impact épidémiologique. Bien que diverses études aient identifié des stratégies offrant une efficacité prouvée dans la réduction des risques d’infection par le VIH et de mortalité par le SIDA, des incertitudes considérables subsistent. Une intégration réussie du traitement et de la prévention du VIH/SIDA suppose une approche équilibrée et une surveillance rigoureuse de l'impact des programmes en matière de résultats individuels et collectifs.

Mots clés: Infection à VIH/prévention et contrôle/chimiothérapie; SIDA/prévention et contrôle/chimiothérapie; Agents antirétroviraux/usage thérapeutique; Thérapie antirétrovirale hautement active/utilisation; Conseil; Transmission verticale maladie/prévention et contrôle; Maladies sexuellement transmissibles/prévention et contrôle; Evaluation résultats traitement; Médecine factuelle; Pays en développement (source: MeSH, INSERM).


Las estrategias empleadas para hacer frente a la epidemia de virus de la inmunodeficiencia humana/síndrome de inmunodeficiencia adquirida (VIH/SIDA) se han servido de diferentes enfoques centrados en la prevención y el tratamiento. Sin embargo, persiste el debate sobre la importancia que debería atribuirse a los diferentes componentes de la respuesta mundial. En el presente artículo se ofrece un panorama de este debate y se resume brevemente la evidencia disponible sobre varias intervenciones diseñadas para prevenir la propagación de la infección por el VIH, prestando especial atención al asesoramiento y las pruebas voluntarias, el tratamiento de las infecciones de transmisión sexual y la prevención de la transmisión de la madre al niño. También examinamos la experiencia acumulada con la terapia antirretroviral hasta la fecha en cuanto a las tasas de respuesta y las tasas de supervivencia, la observancia, la farmacorresistencia, los cambios de comportamiento y el impacto epidemiológico. Aunque diversos estudios han identificado estrategias de demostrada eficacia para reducir el riesgo de infección por VIH y la mortalidad por SIDA, sigue habiendo bastantes interrogantes. Para integrar con éxito el tratamiento y la prevención de la infección por VIH/SIDA se requerirá un enfoque equilibrado y una vigilancia rigurosa del impacto de los programas en términos de resultados tanto individuales como poblacionales.

Palabras clave: Infecciones por VIH/prevención y control/quimioterapia; Síndrome de inmunodeficiencia adquirida/prevención y control/quimioterapia; Agentes antirretrovirales/uso terapéutico Terapia antirretroviral altamente activa/utilización; Consejo; Transmisión vertical de enfermedad/prevención y control; Enfermedades sexualmente transmisibles/prevención y control; Resultado del tratamiento; Medicina basada en evidencia; Países en desarrollo (fuente: DeCS, BIREME).




Strategies for confronting the epidemic of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) have included a range of approaches that focus on prevention and treatment. However, debate persists over the degree of emphasis appropriate to the different components of the global response to the pandemic. Outside wealthy countries, most of the public health interventions for HIV/AIDS have concentrated on prevention. More recently, expansion of antiretroviral therapy (ART) to resource-limited settings has gained prominence as a topic of international debates on HIV/AIDS. In December 2003, WHO launched an initiative to scale up ART delivery to those in need to meet the "3 by 5" target of 3 million people receiving treatment by the end of 2005.

In this paper, in the context of resource-limited settings, we summarize the debate over ART expansion and the evidence on the effectiveness of prevention strategies, especially those interventions likely to be most prominent in efforts to integrate prevention and treatment. We then review the experience gained thus far with ART in resource-limited settings and consider areas of research that may advance the global response to HIV/AIDS.


Evolving paradigms

Efforts to reduce HIV transmission have varied in focus as competing prevention paradigms have captured the interest of decision-makers and funding agencies. Early in the epidemic, an emphasis on "core groups" of transmitters led to prevention efforts being directed towards female sex workers, men who have sex with men (MSM) and intravenous drug users (1). As attention has broadened to include risk behaviours in the wider community, particularly in generalized epidemics such as that in sub-Saharan Africa, more recent debates have revolved around the scope and focus of prevention strategies. The central role of condoms in controlling HIV has been questioned by proponents of the "ABC" approach, which gives priority to "A" (abstinence) and "B" (being faithful) over "C" (condoms) (2). Arguments, put forward primarily by the US Government, for an abstinence-only educational message have been repudiated on scientific grounds, and opponents have cautioned against politicizing school-based education strategies (3).

Although the importance of risk groups and risk behaviour is widely recognized, frustration over limited progress in reducing the incidence of HIV worldwide has bolstered the view that social vulnerability and stigma may hinder the effective implementation of prevention programmes. Calls for treatment as a means to enhance prevention, however, have been accompanied by contentious international debates over scaling up ART in resource-poor settings.

The reservations about the expansion of ART have revolved around the practical challenges of implementing treatment programmes and the high costs of the drugs. In consideration of the severe constraints on human resources in many developing countries and the limited capacity to monitor CD4 cell counts and viral loads, those urging caution in scaling up ART have pointed out that inadequate oversight and care could lead to negligible improvements in survival coupled with the development of drug resistance (4, 5). Opponents of ART expansion have frequently used arguments related to cost-effectiveness, suggesting that greater health gains could be realized for a given financial investment if it were devoted to prevention rather than treatment. For example, one study estimated that ART would cost US$ 1100—1800 per disability-adjusted life year (DALY) averted, whereas preventive interventions such as voluntary counselling and testing (VCT) or condom distribution would cost US$ 18—22 and US$ 1—99 per DALY averted, respectively (6). Another study concluded that the cost of treatment was at least 28 times higher per DALY averted than that of average prevention programmes (7). Although pressure from advocacy groups and the advent of generic drugs have reduced the costs of antiretrovirals precipitously, from more than US$ 10 000 to as low as US$ 140 per patient-year (8), some cost-effectiveness differential between prevention and treatment is likely to persist (6).

Proponents of ART scale-up in developing countries have invoked human rights arguments (9) and challenged the relevance of cost-effectiveness (10). Some experts, citing a failure of past efforts to control the epidemic, expect widespread ART to reduce stigma, increase uptake of voluntary testing, enhance community acceptance of other important prevention programmes, and to contribute directly to interrupting transmission by suppressing viral load and providing new opportunities for counselling on safe sexual behaviour (11, 12). Critics of cost-effectiveness studies point to a range of health, social and economic benefits that are not captured in these analyses — scaling up ART could strengthen the infrastructure for basic health-care delivery and increase the total amount of money available for health rather than drawing resources away from other health programmes (11, 13). Others have noted that treatment programmes could aid development efforts by boosting economic productivity and limiting the social disruption caused by the HIV/AIDS epidemic (14).


Evidence on effectiveness of prevention

Grassly et al. (15) presented a useful framework for assessing the effectiveness of prevention within particular epidemiological contexts. They noted that most studies had evaluated intermediate indicators such as changes in behaviour (e.g. condom use, reduction in the number of sexual partners and treatment-seeking for sexually transmitted infections (STIs)) rather than epidemiological outcomes such as changes in incidence or mortality. Often, these studies combined multiple interventions, which complicated the evaluation of the contributions made by the separate components to the overall observed benefits. Furthermore, because the studies were conducted in specific controlled settings, the generalizability and replicability of successful prevention trials is not guaranteed. Despite these limitations, however, an examination of the existing evidence indicates that a number of different intervention strategies can be effective in reducing HIV risk behaviours (6, 15—19) (Table 1).

As interest in the potential for integrated prevention and treatment efforts increases, three preventive interventions may be particularly relevant as components of a comprehensive response to the epidemic: VCT, treatment of STIs and prevention of mother-to-child transmission (pMTCT).

Voluntary counselling and testing

Voluntary counselling and testing combines confidential provision of information on serostatus, counselling for seropositive individuals and education on reducing the risks of transmission. Where antiretrovirals are available, VCT can also identify candidates for pMTCT or AIDS treatment. A large randomized trial in Kenya, Trinidad and Tobago, and the United Republic of Tanzania measured changes in self-reported sexual behaviour among individuals returning for a first follow-up session (82%, n = 2550). Those who had received both counselling and testing reported greater reductions in unprotected sex with non-primary partners than those who had received health information without serostatus results (reductions of 35% and 39% for men and women, respectively, in the VCT arm, versus 13% and 17% in the control arm). The reductions in risk were greater among seropositive than seronegative individuals (20). A cost-effectiveness analysis linked to this study estimated that VCT would cost US$ 13—18 per DALY averted (making the intervention highly attractive when assessed using typical benchmarks) and indicated that VCT is most cost-effective in high-prevalence settings and when administered to couples rather than to individuals (21). Although these and similar results obtained elsewhere are encouraging, less optimistic outcomes have occasionally been reported (22, 23). Moreover, although VCT has been shown to reduce sexual behaviour among participants, the overall effectiveness of VCT programmes will depend on levels of uptake, which may be depressed by stigma and limited access to treatment (24).

Treatment of sexually transmitted infections

Because the presence of another STI has been shown to increase both susceptibility to and transmissibility of HIV, and because most STIs may be cured by antibiotics, treatment of STIs has been considered as a potential HIV prevention measure. The results from three large community-based randomized controlled trials in sub-Saharan Africa provided mixed evidence on whether STI treatment could reduce the incidence of HIV in a community. In Mwanza, United Republic of Tanzania, the incidence of HIV was 40% lower in the intervention arm (using syndromic STI management) than in the control arm of the trial despite no change in sexual behaviour being reported and, surprisingly, despite no significant reductions in prevalence of STIs in the intervention arm (25). In Rakai, Uganda, a trial of mass STI treatment, supplemented by syndromic management in both the intervention and control arms, found no significant difference in HIV incidence, despite significant reductions in the prevalence of syphilis and non-ulcerative infections in the intervention arm (26). A more recent study in Masaka, Uganda compared behavioural interventions, with or without syndromic STI management, to routine government health programmes and found greater condom use and lower prevalence of STIs in the intervention arms, but the incidence of HIV was not significantly different from that in controls (27).

Attempts to explain the apparent discrepancy between the findings of the Mwanza study and those of the two studies in Uganda have pointed to the higher baseline prevalence of non-ulcerative infections and syphilis in Mwanza than in Rakai and Masaka (28); the lesser importance of STI in advanced epidemics such as the one in Rakai (29); the relative importance of non-treatable HSV-2 as a cofactor (29); and previous reductions in sexual behaviour in Uganda (30). Although the three studies give somewhat ambiguous support for the direct impacts of STI treatment on HIV incidence, the biological links between STI and HIV infectivity, combined with the contact that STI treatment encourages between high-risk individuals and public health services, justify continued consideration of a potential role for STI treatment in an integrated response to HIV/AIDS.

Prevention of mother-to-child transmission

An estimated 15—40% of infants born to mothers infected with HIV-1 will become infected themselves (31), and high maternal viral load is the major risk factor for transmission (32). The ACTG 076 study in France and the United States demonstrated that zidovudine could reduce the probability of perinatal transmission of HIV by almost 70% (31), but used relatively expensive and complex protocols typical of high-income countries (oral doses 5 times daily during pregnancy, intravenous administration to the mother intrapartum, and oral doses 4 times daily to the newborn for 6 weeks after birth). For resource-limited settings, there has been interest in the potential impact of short-course regimens. In a study in Thailand, twice-daily doses of zidovudine from 36 weeks of gestation and every 3 hours during labour reduced transmission risks by 50% if the mother did not breastfeed her infant (33). The HIVNET 012 trial in Uganda found a relative transmission risk (at 14—16 weeks) of 0.47 (95% confidence interval (CI) = 0.20—0.64) for a single-dose of nevirapine during labour followed by a single dose given to the infant within 72 hours of birth, when compared with multiple doses of zidovudine administered during labour followed by twice-daily doses given to the infant for 7 days after birth (34). These risk reductions were sustained through 18 months (15.7% (95% CI = 11.5—19.8%) for nevirapine versus 25.8% (95% CI = 20.7—30.8%) for zidovudine) (35). The Petra study in South Africa, Uganda and the United Republic of Tanzania, compared zidovudine plus lamivudine in three different protocols (prepartum, intrapartum and postpartum; intrapartum and postpartum; and intrapartum alone) and found relative risks of HIV infection or death (at week 6 postpartum) of 0.39 (95% CI = 0.24—0.64), 0.64 (95% CI = 0.42—0.97) and 0.97 (95% CI = 0.68—1.38) for the three protocols, respectively, compared to placebo treatment. The convergence of infection levels in the treatment and control arms of the study by the time the infants were 18 months old suggests risks associated with breastfeeding (36).

Taken together, these studies indicate that short courses of antiretroviral therapy can reduce perinatal transmission by approximately 50%. Based on these effectiveness data, subsequent analyses have concluded that pMTCT is cost effective; the costs are of the order of US$ 5—274 per DALY averted, depending on the protocol and coverage level (37).


Prevention programmes in practice

Despite accumulated evidence that interventions aimed at preventing infection can be effective in trial settings, examples of their successful implementation at the national level remain scarce. It is estimated that globally only 5% of pregnant women attending antenatal clinics have access to pMTCT services; 12% of individuals who want testing have access to VCT; and 42% of people at risk of acquiring HIV through unprotected sex can obtain condoms (38).

Thailand and Uganda are among a small number of developing countries notable for having achieved significant reductions in HIV prevalence. In Thailand, efforts to reduce transmission in the commercial sex industry served as a focal point in a more general public campaign centered on a "100% Condom Programme" using the mass media and an established network of STI treatment clinics for education about HIV/AIDS and distribution of free condoms (39). Reductions in the prevalence of HIV in Thai army recruits (3.7% in 1993 compared with 1.9% in 1997) and pregnant women (2.4% in 1995 compared with 1.7% in 1997) accompanied decreases in risky sexual behaviour (increases in condom use among brothel-based sex workers from 87% to 97% and among other sex workers from 56% to 89% between 1993 and 1996; and decreases in extramarital and commercial sex from 22% to 10% between 1990 and 1997) (40).

In Uganda, which is often cited for its comprehensive, multisectoral response to HIV/AIDS (41), attributing epidemiological changes to specific interventions is difficult. Surveillance data from antenatal clinics show reductions in prevalence of at least 50% since the early 1990s; in Kampala, HIV prevalence among pregnant women dropped from 29% in 1992 to 11% in 2000, while in rural areas the median prevalence decreased from 13% to 6% (42). Debates persist over the causes of the reductions in prevalence observed in Uganda (for example, the relative importance of reduction in the number of sexual partners versus condom use), but the government-sponsored public awareness campaigns on HIV/AIDS risks that were run earlier in the epidemic are likely to be an underlying factor (41).


Impact of antiretroviral therapy to date

The primary end-points in studies of the effectiveness of ART have been the reduction in viral load and the increase in CD4 cell count; both are correlated with increased survival rates. Reducing viral load inhibits disease progression and reduces the probability of transmitting infection. Increasing the CD4 count bolsters the ability of the immune system to fight the diseases to which people with AIDS have increased susceptibility. In developed countries, controlled trials of highly active antiretroviral therapy (HAART) — which typically combines two nucleoside reverse transcriptase inhibitors (NRTIs) with a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI) — have shown reductions in viral load to undetectable levels and increases in CD4 counts among patients who had CD4 levels above 200 cells/µl at the initiation of therapy (43). No studies in developing countries have assessed the optimal timing for initiation of treatment, but experience in high-income countries suggests that therapy should be started at CD4 counts of 200—350 cells per µl to maximize patient survival while avoiding unnecessary exposure to ART medications and the resulting side-effects (44).

Treatment response and survival

Recent clinical studies of ART in resource-poor settings have demonstrated virological, immunological and survival benefits comparable to those reported in the industrialized world (45—52) (Table 2). For treatment-naive individuals, median gains in CD4 cell counts ranged from 75—245 per µl, and reductions in viral load ranged from 1.6—3.3 log copies/ml while on HAART. Two-year survival may approach 80%. Of particular interest is the recently published report of a trial in Cameroon of a fixed-dose generic HAART regimen (combining nevirapine, stavudine and lamivudine), in which most of the study participants (92%) already had AIDS. After 24 weeks, 80% of patients had an undetectable viral load, and the probability of surviving and being free of new AIDS-defining events was 85% (46).


In practice, replication of the gains attained in controlled clinical trials depends critically on levels of adherence. At the individual level, adherence is an important determinant of survival, and at the population level, sustained reductions in viral load are essential for reducing transmission. Poor adherence is also linked to the development of drug resistance, which can compromise response to therapy and spread refractory infections (53).

Some authors have suggested that adherence is particularly challenging in resource-poor settings where antiretrovirals may be used without appropriate counselling or tools for monitoring outcomes (5). Although comparisons between studies must be made with caution because of varying definitions and modes of ascertaining adherence, reports of adherence levels above 90% in China (54), Senegal (55) and South Africa (56) are encouraging and compare favourably to those reported from Europe and North America, where adherence is around 70% (57). Drug costs are noted as an important determinant of non-adherence (55); a study in Botswana estimated that adherence would rise from 54% to 74% if drugs were provided free of charge (58). As ART coverage expands in developing countries, a broad spectrum of drugs will be needed to provide effective alternatives for the treatment of those patients who discontinue their regimens due to drug toxicity and adverse events (59).

Drug resistance

Some level of drug resistance is likely to occur in any population in which ART is used, and even at high rates of adherence (>90%) resistance can occur in patients with incomplete viral suppression (60). At the population level, resistance can be monitored by assays in newly infected, treatment-naive individuals. In the United States, the prevalence of drug resistance in this group increased from 5% before 1996 to 10—22% by 2000. This was comparable to rates reported in Europe and much higher than levels reported in Brazil (57, 61). With the exception of Brazil, studies of resistance in the developing world have been limited to monitoring patients over the course of treatment. A study in Senegal found that treatment-naive individuals were less likely than previously treated individuals to develop resistant strains after 18 months of therapy (11.8% versus 41.7%) (62), and in Thailand, the rates of resistance among patients receiving HAART were 12—48% across different drug classes (63). A study in Uganda found higher rates of resistance in patients treated with dual therapy than in those who received HAART (56% and 36% for patients treated with two NRTIs and HAART, respectively) (64).

Behavioural response

The introduction of effective AIDS treatment in Europe and the United States has had mixed effects on sexual behaviour. The Swiss HIV Cohort Study (n = 4723) found no association between unsafe sex and optimal viral suppression for individuals on HAART (65). However, studies of MSM reported increases in unsafe sex with reductions in viral load (66) and increases in prevalence of STIs among those receiving HAART (67). Another concern is the possibility of increased risky sexual behaviour among seronegative individuals in response to the availability of ART. Sexual disinhibition has been most thoroughly documented via increasing rates of gonorrhoea and unprotected sex among MSM in San Francisco, USA (68). The only published study to date to address the sexual behaviour of ART patients in resource-limited settings presents more optimistic results. In Côte d'Ivoire, patients receiving ART were less likely to engage in unprotected sex than individuals not receiving therapy (univariate odds ratio (OR) 0.44 (95% CI = 0.26—0.74), multivariate OR 0.52 (95% CI = 0.29—0.93)) (69). The population-level behavioural response in resource-poor settings has yet to be determined.

Epidemiological impact

In high-income countries, the development and evolution of antiretroviral drugs in the past decade has led to dramatic reductions in AIDS-related mortality. In Europe and North America, the hazard ratio for death in 2001 compared to 1997 was 0.16, and estimated 12-year survival for HIV seroconverters in 2001 was well over 80% (70).

In the developing world, where it was estimated that only 400 000 of the 6 million people in need of ART had access to this treatment at the beginning of 2004 (71), there is little empirical basis on which to gauge the epidemiological impact in areas where scale-up has already begun. The success of widespread AIDS treatment must ultimately be assessed in terms of reductions in both AIDS mortality and HIV incidence. As the principal example for middle-income countries, Brazil's programme of universal free access to ART has produced increases in median survival times from 18 months for patients diagnosed in 1995 to 58 months for those diagnosed in 1996 when HAART was introduced (72). Experts predict that initial application of HAART in resource-limited countries may yield more limited survival gains on average (approximately 3 years) due to the advanced stage of disease of those eligible for treatment and lack of capacity to monitor CD4 count and viral load and to treat opportunistic infections (73). Measuring the incidence of HIV at the population level is challenging, and the impact of ART on the spread of infection remains uncertain.


Looking ahead

The research agenda on effectiveness of prevention and treatment for HIV/AIDS includes a number of promising avenues. Development of microbicides for the protection of women and investigation of the protective effects of male circumcision against HIV transmission are examples of current prevention research. Rapid tests for HIV serostatus are likely to increase uptake of VCT and pMTCT programmes. Cheaper diagnostic tools for monitoring CD4 cell counts and viral loads would allow clinicians in low-income countries to initiate treatment earlier and to prescribe optimal drug regimens, which will improve outcomes (74). Drug combinations that reduce the number of pills and frequency of dosing required, drugs with fewer side-effects and structured interruptions in therapy could all increase patient adherence.

Positioning ART within a comprehensive approach to HIV/AIDS that integrates prevention and treatment will be facilitated by selecting entry points to ART that can provide enhanced prevention services. The "MTCT-Plus" programmes, which aim to provide lifetime treatment to mothers receiving antiretrovirals to prevent neonatal transmission, offer an existing model of intersection between treatment and prevention services (75). Expanding coverage of STI treatment could help identify candidates for ART within high-risk populations and potentially reduce the spread of HIV infection by mitigating transmission cofactors. Another option to extend the reach of VCT and treatment would be to build on tuberculosis control programmes (10). Although availability of treatment is expected to increase uptake of VCT, aggressive community education may be needed in some contexts (76).

Integration of prevention and treatment in practice will require adequate and sustained funding for both sets of activities, and rigorous monitoring and surveillance of the impact of treatment in terms of both clinical results and broader epidemiological consequences. Studies should be initiated at the outset of ART expansion to determine the effect of treatment availability on the sexual behaviour of the individual patients and of the community, as well as on the uptake of prevention programmes such as VCT. Successful expansion of treatment programmes will offer unique opportunities to strengthen monitoring and evaluation capacity through leveraging of the sustained resource commitments that will be needed to deliver effective ART. Indicators of success for the "3 by 5" initiative should go beyond the defining goal of extending treatment to 3 million people in need, to include substantiation of reductions not only in AIDS mortality, but also in the spread of new infections in the community.

This review of the existing evidence on prevention and treatment in HIV/AIDS epidemics points to certain strategies with proven effectiveness, but also highlights those areas where uncertainty persists. Global and national policy responses to the HIV pandemic must proceed before all these uncertainties are resolved. However, efforts to expand the evidence base for these policies must continue in parallel with their implementation, and progress and directions in the scale-up of ART delivery should be re-evaluated regularly as new evidence emerges.



The authors wish to thank Nancy Dorsinville for helpful discussions. Funding was provided by the National Institute on Aging (Grant P01 AG17625).

Conflicts of interest: none declared.



1. Plummer FA, Nagelkerke NJ, Moses S, Ndinya-Achola JO, Bwayo J, Ngugi E. The importance of core groups in the epidemiology and control of HIV-1 infection. AIDS 1991;5 Suppl 1:S169-76.        

2. Green EC. The new AIDS fight; a plan as simple as ABC. New York Times, 1 March 2003;A19.        

3. DiClemente RJ. Preventing sexually transmitted infections among adolescents: a clash of ideology and science. JAMA 1998;279:1574-5.        

4. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001;358:410-14.        

5. Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ 2004;328:280-82.        

6. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359:1635-43.        

7. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002;359:1851-6.        

8. Gutierrez JP, Johns B, Adam T, Bertozzi SM, Edejer TT, Greener R, et al. Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? Lancet 2004;364:63-4.        

9. Mukherjee J. Basing treatment on rights rather than ability to pay: 3 by 5. Lancet 2004; 363:1071-2.        

10. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001;358:404-9.        

11. Mukherjee JS, Farmer PE, Niyizonkiza D, McCorkle L, Vanderwarker C, Teixeira P, et al. Tackling HIV in resource poor countries. BMJ 2003;327:1104-6.        

12. Lamptey PR. Reducing heterosexual transmission of HIV in poor countries. BMJ 2002;324:207-11.        

13. Gupta R, Irwin A, Raviglione MC, Kim JY. Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet 2004;363:320-24.        

14. Dixon S, McDonald S, Roberts J. The impact of HIV and AIDS on Africa's economic development. BMJ 2002;324:232-4.        

15. Grassly NC, Garnett GP, Schwartlander B, Gregson S, Anderson RM. The effectiveness of HIV prevention and the epidemiological context. Bulletin of the World Health Organization 2001;79:1121-32.        

16. Bollinger L, Cooper-Arnold K, Stover J. Where are the gaps? The effects of HIV-prevention interventions on behavioral change. Studies in Family Planning 2004;35:27-38.        

17. Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy and Planning 2003;18:4-17.        

18. Plummer F, Nagelkerke N, Willbond B, Ngugi EN, Moses S, John G, et al. The evidence base for interventions to prevent HIV infection in low to middle-income countries. In: Jha P, Vaz LME, editors. CMH (Commission on Macroeconomics and Health) Working Paper Series, Paper No. WG5. Geneva: Commission on Macroeconomics and Health; 2001;2:1-81.        

19. Merson MH, Dayton JM, O’Reilly K. Effectiveness of HIV prevention interventions in developing countries. AIDS 2000;14 Suppl 2:S68-84.        

20. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counselling and Testing Efficacy Study Group. Lancet 2000;356:103-12.        

21. Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet 2000;356:113-21.        

22. Kawichai S, Beyrer C, Khamboonruang C, Celentano DD, Natpratan C, Rungruengthanakit K, et al. HIV incidence and risk behaviours after voluntary HIV counselling and testing (VCT) among adults aged 19-35 years living in peri-urban communities around Chiang Mai city in northern Thailand, 1999. AIDS Care 2004;16:21-35.        

23. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, Fideli U, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 2003;17:733-40.        

24. Joint United Nations Programme on HIV/AIDS. Voluntary counselling and testing (VCT). Geneva: Joint United Nations Programme on HIV/AIDS; 2000. UNAIDS Technical Update.        

25. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995;346:530-36.        

26. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999;353:525-35.        

27. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003;361:645-52.        

28. Orroth KK, Korenromp EL, White RG, Changalucha J, de Vlas SJ, Gray RH, et al. Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors. Sexually Transmitted Infections 2003;79:98-105.        

29. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000;355:1981-7.        

30. Korenromp EL, Bakker R, de Vlas SJ, Gray RH, Wawer MJ, Serwadda D, et al. HIV dynamics and behaviour change as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial. AIDS 2002;16:2209-18.        

31. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine 1994;331:1173-80.        

32. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. Journal of Infectious Diseases 2001;183:539-45.        

33. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773-80.        

34. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.        

35. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-68.        

36. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178-86.        

37. Scotland GS, van Teijlingen ER, van der Pol M, Smith WC. A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 2003;17:1045-52.        

38. Global HIV Prevention Working Group. Access to HIV Prevention: Closing the Gap. Seattle: Bill & Melinda Gates Foundation and Henry J. Kaiser Family Foundation; 2003.        

39. Ainsworth M, Beyrer C, Soucat A. AIDS and public policy: the lessons and challenges of "success" in Thailand. Health Policy 2003;64:13-37.        

40. Phoolcharoen W. HIV/AIDS prevention in Thailand: success and challenges. Science 1998;280:1873-4.        

41. Okware S, Opio A, Musinguzi J, Waibale P. Fighting HIV/AIDS: is success possible? Bulletin of the World Health Organization 2001;79:1113-20.        

42. UNAIDS/UNICEF/WHO. Uganda epidemiological fact sheets on HIV/AIDS and sexually transmitted infections: 2002 update. Geneva: Joint United Nations Programme on HIV/AIDS/United Nations Children's Fund/World Health Organization; 2002.        

43. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.        

44. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Annals of Internal Medicine 2002;137:381-433.        

45. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.        

46. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364:29-34.        

47. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003;17 Suppl 3:S5-15.        

48. Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003;17:2267-9.        

49. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003;17:1017-22.        

50. Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndrome 2001;27:116-23.        

51. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002;16:1363-70.        

52. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002;360:34-40.        

53. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83.        

54. Fong OW, Ho CF, Fung LY, Lee FK, Tse WH, Yuen CY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine 2003;4:133-8.        

55. Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003;17 Suppl 3:S103-8.        

56. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003;17:1369-75.        

57. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-11.        

58. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndrome 2003;34:281-8.        

59. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clinical Infectious Diseases 2003;37:714-22.        

60. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-32.        

61. Dumans AT, Soares MA, Pieniazek D, Kalish ML, De Vroey V, Hertogs K, et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrobial Agents and Chemotherapy 2002;46:3075-9.        

62. Vergne L, Kane CT, Laurent C, Diakhate N, Gueye NF, Gueye PM, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003;17 Suppl 3:S31-8.        

63. Jenwitheesuk E, Watitpun C, Vibhagool A, Chantratita W. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Annals of Clinical Microbiology and Antimicrobials 2003;2:4.        

64. Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative — Uganda. AIDS 2003;17 Suppl 3:S39-48.        

65. Wolf K, Young J, Rickenbach M, Vernazza P, Flepp M, Furrer H, et al. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndrome 2003;33:494-9.        

66. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001;15:369-78.        

67. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001;357:432-5.        

68. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. American Journal of Public Health 2002;92:388-94.        

69. Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Côte d'Ivoire. AIDS 2003;17 Suppl 3: S69-77.        

70. Cascade Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-74.        

71. World Health Organization. The world health report 2003 — shaping the future. Geneva: World Health Organization; 2003.        

72. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82.        

73. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact. Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. AIDS 2002;16:W1-14.        

74. Stephenson J. Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment. JAMA 2002;288:151-3.        

75. Mitka M. MTCT-Plus program has two goals: end maternal HIV transmission + treat mothers. JAMA 2002;288:153-4.        

76. Day JH, Miyamura K, Grant AD, Leeuw A, Munsamy J, Baggaley R, et al. Attitudes to HIV voluntary counselling and testing among mineworkers in South Africa: will availability of antiretroviral therapy encourage testing? AIDS Care 2003;15:665-72.        



Submitted: 29 April 2004 — Final revised version received: 25 October 2004 — Accepted: 29 October 2004



1 Correspondence should be sent to Dr Salomon at this address (email:

World Health Organization Genebra - Genebra - Switzerland